Myriad Genetics
January 25, 2019
Myriad discovers and commercializes genetic tests that determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs.
Recent News
- BioSeeker™ Powers Development of a First-of-Its-Kind Programmable Therapeutic for Respiratory Syncytial Virus (RSV)
- Canary Speech Achieves HITRUST e1 Certification for Voice Biomarker Platform
- Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
- Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
- GE HealthCare’s Economic Impact Across Utah
- RefloDx Wins Trans Atlantic Angel Grand Prize